- Home
- DNLI vs RCUS Comparison
DNLI vs RCUS Comparison
Compare DNLI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | RCUS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DNLI | RCUS |
|---|---|---|
| Price | $18.95 | $18.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 15 |
| Target Price | $35.50 | ★ $41.00 |
| AVG Volume (30 Days) | 1.6M | ★ 2.2M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $157.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.75 | $17.43 |
| 52 Week High | $27.30 | $31.74 |
Technical Indicators
Market Signals| Indicator | DNLI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 29.48 |
| Support Level | $17.75 | $17.97 |
| Resistance Level | $19.35 | $24.80 |
| Average True Range (ATR) | 0.77 | 1.65 |
| MACD | 0.21 | -0.25 |
| Stochastic Oscillator | 61.22 | 8.46 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.